Myeloid-Derived Suppressor Cells Associated with Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition

Journal of Acquired Immune Deficiency Syndromes

Volumn 76, Issue 2, 2017, Pages 200-208

  Zhang, Zi Ning ^a,b   Yi, Nan ^a,c   Zhang, Tong Wei ^a   Zhang, Le Le ^a,b   Wu, Xian ^a,b   Liu, Mei ^a,b   Fu, Ya Jing ^a,b   He, Si Jia ^a,b   Jiang, Yong Jun ^a,b   Ding, Hai Bo ^a,b   Chu, Zhen Xing ^a,b   Shang, Hong ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Gal 9; HIV; myeloid derived suppressor cells; PD L1; primary HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; ECALECTIN; GAMMA INTERFERON; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; ANTIRHEUMATIC AGENT; CD274 PROTEIN, HUMAN; GALECTIN; LGALS9 PROTEIN, HUMAN;

ACUTE HIV INFECTION; ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MYELOID-DERIVED SUPPRESSOR CELL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHRONIC DISEASE; CYTOLOGY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONONUCLEAR CELL; SECRETION (PROCESS); YOUNG ADULT;

ADULT; ANTIGENS, CD274; ANTIRHEUMATIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GALECTINS; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MYELOID-DERIVED SUPPRESSOR CELLS; VIRAL LOAD; YOUNG ADULT;

EID: 85020189057     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001471     Document Type: Article

References (50)

1. Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med. 2011;364:1943-1954.
2. Streeck H, van Bockel D, Kelleher A. T-cell responses in primary HIV-1 infection. Curr Opin HIV AIDS. 2008;3:52-59.
3. Korner C, Granoff ME, Amero MA, et al. Increased frequency and function of KIR2DL1-3(+) NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes. Eur J Immunol. 2014;44:2938-2948.
4. Sabado RL, O'Brien M, Subedi A, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010;116:3839-3852.
5. Schieffer M, Jessen HK, Oster AF, et al. Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J Virol. 2014;88:7357-7366.
6. Li Z, Li W, Li N, et al. Gammadelta T cells are involved in acute HIV infection and associated with AIDS progression. PLoS One. 2014;9: e106064.
7. Fernandez CS, Kelleher AD, Finlayson R, et al. NKT cell depletion in humans during early HIV infection. Immunol Cell Biol. 2014;92: 578-590.
8. Falivene J, Ghiglione Y, Laufer N, et al. Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression. Sci Rep. 2015;5:11511.
9. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947.
10. Alter G, Merchant A, Tsoukas CM, et al. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis. 2002;185:755-765.
11. Chevalier MF, Didier C, Petitjean G, et al. Phenotype alterations in regulatory T-cell subsets in primary HIV infection and identification of Tr1-like cells as the main interleukin 10-producing CD4+ T cells. J Infect Dis. 2015;211:769-779.
12. Al-Harthi L, MaWhinney S, Connick E, et al. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007;125: 299-308.
13. Kloverpris HN, Kazer SW, Mjosberg J, et al. Innate Lymphoid cells are depleted Irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity. 2016;44:391-405.
14. Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and Kinetics of CD8+ T cell activation during Hyperacute HIV infection impact viral set point. Immunity. 2015;43:591-604.
15. Ferrando-Martinez S, Ruiz-Mateos E, Romero-Sanchez MC, et al. HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. Curr HIV Res. 2011;9:289-294.
16. Ghiglione Y, Falivene J, Ruiz MJ, et al. Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One. 2014;9:e104235.
17. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19-25.
18. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
19. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11:802-807.
20. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res. 2013;57:172-184.
21. Lei A, Yang Q, Cai W, et al. Clinical significance of myeloid-derived suppressor cells in HIV-1/HCV Coinfected patients. Scand J Immunol. 2016;83:438-444.
22. Mehraj V, Jenabian MA, Vyboh K, et al. Immune suppression by myeloid cells in HIV infection: new targets for Immunotherapy. Open AIDS J. 2014;8:66-78.
23. Vollbrecht T, Stirner R, Tufman A, et al. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS. 2012;26:F31-F37.
24. Qin A, Cai W, Pan T, et al. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol. 2013;87:1477-1490.
25. Tumino N, Turchi F, Meschi S, et al. HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3zeta expression through ELF-1 inhibition. AIDS. 2015;29:2397-2407.
26. Manjili MH, Wang XY, Abrams S. Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs. Front Immunol. 2014;5:303.
27. Thevenot PT, Sierra RA, Raber PL, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41:389-401.
28. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253-268.
29. Garg A, Spector SA. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis. 2014;209:441-451.
30. Pinton L, Solito S, Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2016;7:1168-1184.
31. Dubinski D, Wolfer J, Hasselblatt M, et al. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2016;18: 807-818.
32. Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor Trafficking Enhances anti-PD1 Efficacy. Sci Transl Med. 2014;6:237-267.
33. Lei GS, Zhang C, Lee CH. Myeloid-derived suppressor cells Impair Alveolar macrophages through PD-1 Receptor Ligation during pneumo-cystis pneumonia. Infect Immun. 2014;83:572-582.
34. Yu GT, Bu LL, Huang CF, et al. PD-1 blockade attenuates immuno-suppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6:4267-4280.
35. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781-790.
36. van der Merwe M, Abdelsamed HA, Seth A, et al. Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation. J Immunol. 2013;191:5764-5776.
37. Fujimura T, Ring S, Umansky V, et al. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132:1239-1246.
38. Dardalhon V, Anderson AC, Karman J, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol. 2010;185:1383-1392.
39. Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol. 2009;83:7641-7648.
40. Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. JLeukoc Biol. 2015;98:913-922.
41. Condamine T, Gabrilovich DI. Can the suppressive activity of myeloid-derived suppressor cells Be "Chop"ped? Immunity. 2014;41:341-342.
42. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33:23-35.
43. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 1987;47:100-105.
44. Leone A, Picker LJ, Sodora DL. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Curr HIV Res. 2009;7:83-90.
45. Wu T, Zhao Y. The roles of myeloid-derived suppressor cells in transplantation. Expert Rev Clin Immunol. 2014;10:1385-1394.
46. Wesolowski R, Markowitz J, Carson WE III. Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10.
47. Wang Y, Tian J, Wang S. The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis. Semin Arthritis Rheum. 2016;45:490-495.
48. Liu W, Tong Z. Evaluation of immune Restoration potential of PD-1 blockers. J Immunoassay Immunochem. 2015;36:567-572.
49. Brockman MA, Kwon DS, Tighe DP, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 2009;114:346-356.
50. Ndhlovu LC, Loo CP, Spotts G, et al. FOXP3 expressing CD127lo CD4 + T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol. 2008;83:254-262.